在免疫抑制和骨髓抑制下,对tofacitinib的快速和持续反应
Yuting Zhou1, Long Zhang2, Wenhui Wang1
1Department of Dermatology, Peking University Third Hospital, Beijing, China.
在免疫抑制患者中,托法西替尼有效治疗了耐火性皮肤病 (PG). 这种Janus激酶抑制剂可快速缓解症状,几乎完全治愈,没有任何不良反应.
科学领域:
- 免疫学
- 皮肤病学
- 药理学
背景情况:
- 皮肤炎 (PG) 是一种罕见的性中性质皮肤病.
- 耐药性PG会给患者带来重大治疗挑战,尤其是在患有并发症和免疫抑制的患者中.
- 现有疗法通常具有有限的疗效或显著的副作用.
研究的目的:
- 评估托法西替尼在耐火性近皮质性瘤治疗中的疗效和安全性.
- 评估托法西提尼布在患有免疫抑制和骨髓抑制的患者的使用情况.
- 探索Janus激酶 (JAK) 抑制作为复杂PG病例的向治疗方法.
主要方法:
- 一个62岁男性的病例研究,
- 患者在治疗前尼索隆和塔克罗利时有纯红细胞无形成症和肌痛性肌痛症.
- 经过多学科评估后进行了口服托法西替尼 (5 mg/ 天).
主要成果:
- 在开始使用tofacitinib后的两天内显著减少疼痛.
- 在治疗后两周内观察到几乎完全的愈.
- 血液学参数稳定,耐受性良好,在4个月内没有不良事件;1年没有复发.
结论:
- 托法西替尼为耐火性PG提供了快速,有效和良好的治疗方法.
- 即使在基线免疫抑制患者中,它也显示出前景.
- 在复杂的PG呈现中,JAK抑制剂是潜在的向治疗.
更多相关视频
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
